Kidney function and kidney cancer risk are among the health outcomes with epidemiological associations to PFAS exposure. The kidneys are the primary route for PFAS elimination from the body, making them an organ of particular relevance in PFAS toxicology and suggesting specific concern for individuals with kidney disease.
PFAS Elimination Through the Kidneys
Perfluoroalkyl acids are primarily eliminated from the body through urinary excretion via renal tubular transport. The efficiency of this excretion varies significantly by PFAS compound, contributing to the wide range of half-lives among PFAS — from weeks for some short-chain compounds to years for PFOA and PFOS. The kidney’s role as a primary excretion organ means it is continuously exposed to PFAS during the excretion process, potentially explaining PFAS-related kidney effects.
Kidney Cancer Risk
PFOA is classified as possibly carcinogenic to humans by the International Agency for Research on Cancer (IARC), with kidney cancer among the outcomes evaluated in occupationally exposed populations. Epidemiological evidence for kidney cancer has been found primarily at high occupational exposures, with environmental exposure evidence more limited. However, the mechanistic plausibility is well-established through animal data, supporting precautionary exposure reduction.
Implications for Kidney Disease Patients
Individuals with chronic kidney disease have reduced PFAS excretion capacity, leading to higher PFAS body burden accumulation for equivalent intake compared to individuals with normal kidney function. For this population, reducing PFAS intake through certified water filtration is particularly important, as their impaired elimination means that ongoing exposure leads to faster body burden accumulation than in the general population.